To evaluate whether laxatives and fibre therapy improve symptoms and bowel movement frequency in adults with chronic constipation.
Outcomes assessed in the review
Mean bowel movement frequency per week; symptom improvement, and reduction in abdominal pain; need for breakthrough laxatives; and stool consistency. Not all trials included assessment of all of these outcomes.
How were decisions on the relevance of primary studies made?
Two independent reviewers selected the papers for the review.
Assessment of study quality
Validity was assessed using a 6-point scale assessing inclusion and exclusion criteria, randomisation method, whether adverse effects were assessed in a standardised fashion, double-blinding, description of withdrawals, and statistical analysis. These criteria were used in the overall narrative summary of the studies. Two independent reviewers performed the validity assessment.
Data extraction
Two independent reviewers extracted the data for the review.
Methods of synthesis
How were the studies combined? The studies were combined by a narrative review, and also statistically by calculating an overall weighted average for the bowel movement frequency data.
How were differences between studies investigated?
Database Differences between the studies were investigated by a narrative review.
Results of the review
Thirty-six trials were identified which met the inclusion criteria. These included a total of 1,815 participants.
Twenty trials compared treatment to a placebo, usual care, or discontinuation of laxative control group. Sixteen trials directly compared different treatments.
Bowel movement frequency results: laxatives and fibre increased bowel movement frequency by an overall weighted average of 1.4 (95% confidence interval, CI: 0.6, 2.2) bowel movements per week. The trials evaluating agents other than bulk laxatives showed a mean increase with treatment of 1.5 bowel movements per week (95% CI: 1.1, 1.8).
Need for additional laxatives: the trials reporting on breakthrough laxative use showed that patients assigned to treatment had less need for such laxatives than control patients.
Symptoms: fibre and bulk laxatives decreased abdominal pain and improved stool consistency compared with placebo. Most nonbulk laxative data concerning abdominal pain and stool consistency were inconclusive, though cisapride, lactulose, and lactitol improved consistency. The data concerning superiority of various treatments were inconclusive.
Two trials assessing general well-being showed no significant group differences between treatments.
Side-effects: no severe side-effects were reported for any of the therapies.
Authors' conclusions
Fibre and laxatives modestly increase bowel movement frequency, while fibre and bulk laxatives improve symptoms such as stool consistency and pain. There is too little evidence to determine whether one laxative treatment is better than another.
CRD commentary
This is a good quality review that highlights the lack of research into the treatment of this common problem.
Implications of the review for practice and research
Practice: Laxatives and fibre appear to work better than placebo, but since there is so little research in this area, it is impossible to determine what the most appropriate treatment is for different types of patient (e.g. mobile versus immobile patients), or what type of laxative is most effective. There appears to be little indication that pharmacological laxatives are much more effective than simple treatments such as fibre and dietary interventions. This would suggest that a first-line of approach to treatment would involve dietary interventions, followed by treatment with pharmacological laxatives if this proved ineffective.
Research: There is a real lack of research into treatment of constipation. In particular, trials are required comparing different types of laxative therapy. In the UK at least, expensive stimulant laxatives are widely used, though there appears to be little evidence that these are more effective than cheaper alternatives. Trials comparing the more expensive treatments to cheaper laxatives are therefore indicated. This would allow the effectiveness and costeffectiveness of different treatments to be established. Finally, many of the published trials have been statistically underpowered, and therefore, lack the power to detect differences between treatments if they existed. Future trials should be of adequate size and methodologically sound (e.g. double-blinded, with standardised assessment of adverse effects, and properly randomised). 
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